Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.43 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.40 |
| ▸ | TYMP | P19971 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL28760132 | 0.94 | ACP3 (0.42) | DNMT1ACP3PTK2BL3MBTL1WDR5 | |
| SCHEMBL28080572 | 0.87 | WDR5 (0.47) | DNMT1ACP3PTK2BL3MBTL1WDR5 | |
| SCHEMBL29397823 | 0.81 | GPR84 (0.43) | DNMT1ACP3PTK2BL3MBTL1HDAC8 | |
| SCHEMBL27902996 | 0.80 | ACP3 (0.46) | ACP3PTK2BL3MBTL1HDAC8HDAC6 | |
| SCHEMBL6242989 | 0.80 | DNMT1 (0.41) | DNMT1L3MBTL1WDR5HDAC8HDAC6 | |
| Phosphoric Acid SCHEMBL31219446 | 0.79 | NSD2 (0.51) | DNMT1ACP3GPR84MEN1MAPT | |
| Phosphoric Acid SCHEMBL29768762 | 0.79 | NSD2 (0.51) | DNMT1ACP3GPR84MEN1MAPT | |
| Phosphoric Acid SCHEMBL3922368 | 0.79 | NSD2 (0.51) | DNMT1ACP3GPR84MEN1MAPT | |
| Phosphoric Acid SCHEMBL547015 | 0.79 | ACP3 (0.55) | ACP3PTK2BL3MBTL1HDAC8HDAC6 | |
| Phosphoric Acid SCHEMBL29911372 | 0.79 | ACP3 (0.55) | ACP3PTK2BL3MBTL1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118751288-A | Preparation method of propenyl binaphthyl phosphonic acid/Pt-loaded hollow mesoporous nanospheres, product and application thereof | 重庆邮电大学 | 2024-10-11 | — | — | CN | claimed |
| CN-118751288-A | Preparation method of propenyl binaphthyl phosphonic acid/Pt-loaded hollow mesoporous nanospheres, product and application thereof | 重庆邮电大学 | 2024-10-11 | — | — | CN | disclosed |
| CN-118751288-A | Preparation method of propenyl binaphthyl phosphonic acid/Pt-loaded hollow mesoporous nanospheres, product and application thereof | 重庆邮电大学 | 2024-10-11 | — | — | CN | disclosed |
| CN-108084129-B | Method for synthesizing (1S, 5R) -lactone | 复旦大学 | 2022-09-16 | — | — | CN | disclosed |
| US-11441163-B2 | Enzyme-catalyzed synthesis of (1S,5R)-bicyclolactone | FUDAN UNIVERSITY (CN) | 2022-09-13 | — | — | US | disclosed |
| US-20210355516-A1 | ENZYME-CATALYZED SYNTHESIS OF (1S,5R)-BICYCLOLACTONE | FUDAN UNIVERSITY (CN) | 2021-11-18 | — | — | US | disclosed |
| US-10316012-B1 | Method of synthesizing (1S, 5R)-lactone | FUDAN UNIVERSITY (CN) | 2019-06-11 | — | — | US | disclosed |
| EP-1888604-B1 | PROCESS FOR PREPARING (ALPHA S, BETA R)-6-BROMO-ALPHA-[2-(DIMETHYLAMINO)ETHYL]-2-METHOXY-ALPHA-1-NAPHTHALENYL-BETA-PHENYL-3-QUINOLINEETHANOL | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-14 | — | — | EP | disclosed |
| EP-0451008-B1 | 8-Sulfamylmethylene-2-amino tetralins | MERRELL DOW PHARMA (US) | 1995-06-28 | — | — | EP | disclosed |
| EP-0451008-A1 | 8-Sulfamylmethylene-2-amino tetralins | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-10-09 | — | — | EP | disclosed |
| EP-0450238-A1 | Novel compounds for the treatment of migraine | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-10-09 | — | — | EP | disclosed |
| EP-0451022-A1 | Novel compounds for the treatment of migraine | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-10-09 | — | — | EP | disclosed |
| EP-0447727-A1 | Novel 8-sulfamylmethylene-2-amino tetralins | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316012-B1 | Method of synthesizing (1S, 5R)-lactone | HAO2, HAO1, OXER1 | DNMT1 1930/4885ACP3 1077/4885PTK2B 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.